Target type: biologicalprocess
The directed movement of folic acid from outside of a cell, across the plasma membrane and into the cytosol. [GO_REF:0000075, GOC:BHF, GOC:hal, GOC:TermGenie, PMID:19762432]
Folate import across the plasma membrane is a complex process involving several steps. It begins with the binding of folate to a specific receptor protein on the cell surface, called the folate receptor. This receptor is highly expressed on rapidly dividing cells, including cancer cells, making it a potential target for cancer therapy. Once bound, the receptor-folate complex undergoes endocytosis, a process where the plasma membrane invaginates and pinches off, forming a vesicle containing the complex. This vesicle then travels to the cell's interior, where it fuses with a lysosome, an organelle containing enzymes that degrade the receptor and release folate into the cytoplasm. Folate is then transported to the mitochondria, where it is used in the synthesis of tetrahydrofolate (THF), a critical cofactor for many metabolic reactions, including DNA synthesis, nucleotide synthesis, and amino acid metabolism. In addition to the receptor-mediated pathway, folate can also be transported across the plasma membrane through a passive diffusion process. However, this process is less efficient and is likely to be of lesser importance compared to the receptor-mediated pathway. Overall, the import of folate across the plasma membrane is a crucial process for cell growth and proliferation, and its dysregulation can lead to various diseases, including folate deficiency and cancer.'
"
Protein | Definition | Taxonomy |
---|---|---|
Proton-coupled folate transporter | A proton-coupled folate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q96NT5] | Homo sapiens (human) |
Reduced folate transporter | A reduced folate transporter that is encoded in the genome of human. [PRO:DNx, UniProtKB:P41440] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
methotrexate | dicarboxylic acid; monocarboxylic acid amide; pteridines | abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent | |
10-propargyl-10-deazaaminopterin | 10-propargyl-10-deazaaminopterin: structure in first source pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma. | N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound | antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor |
raltitrexed | N-acyl-amino acid | ||
pemetrexed | pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). | N-acyl-L-glutamic acid; pyrrolopyrimidine | antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor |